colesevelam
Sign in to saveColesevelam is a bile acid sequestrant administered orally. It was developed by GelTex Pharmaceuticals and later acquired by Genzyme. It is marketed in the US by Daiichi Sankyo under the brand name Welchol and elsewhere by Genzyme as Cholestagel. In Canada, it is marketed by Valeant as Lodalis.
Research
381 papers- Colesevelam hydrochloride.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2002
- Colesevelam.2012
- Colesevelam.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2001
- Colesevelam.2006
- Colesevelam.2026
via PubMed
Article
5 sectionsContents
- Clinical use
- Constituents
- Mechanism of action
- Side effects
- References
Colesevelam is a bile acid sequestrant administered orally. It was developed by GelTex Pharmaceuticals and later acquired by Genzyme. It is marketed in the US by Daiichi Sankyo under the brand name Welchol and elsewhere by Genzyme as Cholestagel. In Canada, it is marketed by Valeant as Lodalis.
==Clinical use== Colesevelam is indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in patients with primary hyperlipidemia as monotherapy and to improve glycemic control in adults with type 2 diabetes mellitus, including in combination with a statin. The expanded use of colesevelam in adults with type 2 diabetes mellitus is an example of drug repositioning.